Skip to content

Homoeopathy in Acute Ischemic Stroke

Homoeopathy as an adjuvant to the standard therapy in Acute Ischemic Stroke: an exploratory, single blind, randomized controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089901
Enrollment
50
Registered
2025-06-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I639- Cerebral infarction, unspecified

Interventions

Intervention1: Standard Therapy+ Indivisualized Homoeopathic medicine: Homoeopathic medicines will be given to this group patients as an add-on to standard therapy. Following Individualization medicin

Sponsors

Central Council for Research in Homoeopathy
Lead Sponsor
HiTech Medical College and Hospital
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age group: 18 years and above. 2) Both genders. 3) Confirmed diagnosed case of Acute Ischemic Stroke (confirmation done by MRI Brain/ NCCT Head at time of enrolment of patient). 4) Stroke episode having duration of symptoms of more than 6 hours. 5) NIHSS from 5 to 20 (including moderate to severe stroke episode).

Exclusion criteria

Exclusion criteria: 1) Experienced chest discomfort for greater than 15 minutes and less than 12 hours. 2) History of structural Central Nervous System disease (tumors, masses, hemorrhage, etc.) 3) Significant closed head or facial trauma within the previous 3 months. 4) Recent (within 6 weeks) major trauma, surgery (including laser eye surgery), gastrointestinal bleeding or genital-urinary bleeding. [Serious systemic bleeding is defined as potentially life-threatening bleeding which requires immediate medical intervention] 5) Papilledema. 6) Bleeding or clotting problem or patient on blood thinners. 7) Serious Systemic Disease such as advanced/terminal cancer or severe liver or kidney failure. 8) Pregnant females. 9) Lactating mothers. 10) Patients unwilling to give consent.

Design outcomes

Primary

MeasureTime frame
The primary outcome will be assessment of neurological deficit following stroke as measured by National Institute of Health Stroke Scale (NIHSS) assessed at baseline, 3rd, 5th, 7th, 10th and 90th day.Timepoint: Baseline, 3rd, 5th, 7th, 10th and 90th day.

Secondary

MeasureTime frame
Number of deaths reported in two groups during 10 days.Timepoint: Baseline and 10th day.;Modified Rankin scale (mRS) assessment at baseline and 90th day.Timepoint: Baseline and 90th day.;Time to reach score 8 on NIHSS scaleTimepoint: Baseline, 3rd, 5th, 7th, 10th and 90th day.;Adverse events during 10 days.Timepoint: Baseline, 3rd, 5th, 7th, 10th and 90th day.;Level of CRP, IL-6 and d-dimer.Timepoint: Baseline, 3rd, 5th, 7th, 10th and 90th day.

Countries

India

Contacts

Public ContactSubhankar Mishra

Central Council for Research in Homoeopathy

ccrh.dengue@gmail.com09873404012

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026